A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

NCT07736001 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Tumor Patients

Interventions

DRUG: Trilaciclib and Topoisomerase I inhibitor type ADC drugs

Sponsor

Tianjin Medical University Cancer Institute and Hospital